Advancements in ADC Therapy for Metastatic Triple Negative and HER+/HER2- Breast Cancer Treatment
Oncology0.75 AMA PRA Category 1 Credit(s) ™
December 23, 2024
December 23, 2025
Primary Audience:
Medical oncologists and oncology nurse practitioners (NPs) and physician associates (PAs) who care for patients with breast cancer.
Relevant Terms:
Oncology, Breast Cancer, mTNBC, HER2+, HER2-low, HER2-, solid tumor
Sara M. Tolaney, MD, MPH
Chief, Division of Breast Oncology, Susan F. Smith Center for Women's Cancers
Associate Director, Susan F. Smith Center for Women's Cancers
Associate Professor of Medicine, Dana Farber Cancer Institute
Dr. Tolaney received her undergraduate degree from Princeton University in 1998 and her medical degree from UC San Francisco in 2002. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained a Masters in Public Health from the Harvard School of Public Health in 2007. In 2008, she joined the staff of Dana-Farber Cancer Institute and Brigham and Women's Hospital, where she serves as Chief of the Division of Breast Oncology. She is a breast medical oncologist whose research focuses on the development of novel therapies in the treatment of breast cancer. She has been instrumental in developing several treatment approaches for breast cancer, including approaches focused on tailoring therapy for early stage HER2+ disease, use of CDK 4/6 inhibitors, antibody drug conjugates, and immunotherapy.David B. Page, MD
Medical Oncologist
Clinical Investigator
Providence Cancer Institute
Dr. David Page is a medical oncologist and clinical investigator at the Providence Cancer Institute in Portland, Oregon. His area of expertise is in the field of breast cancer immunotherapy.
He completed a Bachelor’s of the Arts at the University of Chicago, a medical doctorate at Northwestern University, followed by internal medicine residency at Columbia University / New York Presbyterian and medical oncology fellowship at Memorial Sloan Kettering Cancer Center in New York City.
He has conducted and published outcomes of numerous investigator-initiated trials, including trials combining immune checkpoint blockade with chemotherapy, radiotherapy, and novel targeted/immune therapies in breast cancer, both in the curative and metastatic setting. He also has served on various immunotherapy-related committees, including the NCI Breast Immuno-oncology task force, the SITC Breast Immunotherapy expert panel, and the SITC multispectral immunofluorescence working group.
| 1. | APPLY data from recent clinical trials using ADCs in the treatment of TNBC to sequencing strategies in patient care | 2. | OPTIMIZE treatments for patients with HR+/HER2- breast cancer using data from recent clinical trials of ADCs |
| 3. | DEVELOP a plan to monitor for and manage AEs in patients with breast cancer treated with ADCs, in order to avoid interruptions in care |
| 1. | APPLY data from recent clinical trials using ADCs in the treatment of TNBC to sequencing strategies in patient care |
| 2. | OPTIMIZE treatments for patients with HR+/HER2- breast cancer using data from recent clinical trials of ADCs |
| 3. | DEVELOP a plan to monitor for and manage AEs in patients with breast cancer treated with ADCs, in order to avoid interruptions in care |
TITLE: Advancements in ADC Therapy for Metastatic Triple Negative and HER+/HER2- Breast Cancer Treatment
Release Date: December 23, 2024
Expiration Date: December 23, 2025
STATEMENT OF NEED
Breast cancer continues to be a leading cause of cancer-related deaths globally, with HER2-positive, HER2-low, and triple-negative breast cancer (mTNBC) presenting unique challenges. Antibody-drug conjugates (ADCs) are transforming the treatment landscape, offering targeted therapy options that improve efficacy while reducing systemic toxicity. Despite these advancements, many HCPs face challenges in understanding how to incorporate ADCs into clinical practice, including selecting the right patients, sequencing treatments, and managing side effects. This curriculum is designed to close those gaps, equipping participants with the latest evidence and practical tools to optimize care for patients with these challenging breast cancer subtypes.
EDUCATIONAL OBJECTIVES
- APPLY data from recent clinical trials using ADCs in the treatment of TNBC to sequencing strategies in patient care
- OPTIMIZE treatments for patients with HR+/HER2- breast cancer using data from recent clinical trials of ADCs
- DEVELOP a plan to monitor for and manage AEs in patients with breast cancer treated with ADCs, in order to avoid interruptions in care
TARGET AUDIENCE:
This educational initiative is intended for medical oncologists and oncology nurse practitioners (NPs) and physician associates (PAs) who care for patients with breast cancer.
FACULTY
|
|
Sara M. Tolaney, MD, MPH Chief, Division of Breast Oncology, Susan F. Smith Center for Women's Cancers
|
|
|
David B. Page, MD Medical Oncologist
|
CONTENT REVIEWER
Victor B. Hatcher, PhD
DISCLOSURE OF FINANCIAL RELATIONSHIPS
The “Policy on Identification, Mitigation, and Disclosure of Relevant Financial Relationships” of Albert Einstein College of Medicine-Montefiore Medical Center requires that any individual in control of content, including faculty, participating in CME activities disclose to the audience all relevant financial relationships with ineligible companies* in the past 24 months. Any individual in control of content who refuses to disclose, or whose disclosed relationships prove to create a conflict of interest, will be recused.
Individuals with the absence of relevant financial relationships with ineligible companies will be disclosed to the audience.
All financial relationships of individuals in a position to control the content of this CME activity are identified and mitigated prior to the educational activity.
*The ACCME defines an ineligible company as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Faculty Disclosure(s)
Victor B. Hatcher, PhD has no relevant financial relationships with ACCME-defined ineligible companies during the past 24 months.
David B. Page, MD, has no relevant financial relationships with ACCME-defined ineligible companies during the past 24 months.
Sara M. Tolaney, MD, MPH has no relevant financial relationships with ACCME-defined ineligible companies during the past 24 months.
PROVIDERSHIP
This educational activity is jointly provided by Albert Einstein College of Medicine-Montefiore Medical Center and RealCME.
ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and RealCME, LLC. Albert Einstein College of Medicine-Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CREDIT DESIGNATION STATEMENT
Albert Einstein College of Medicine-Montefiore Medical Center designates this other activity (blended live and enduring curriculum) for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Credits
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of .75 hours of Category 1 credit for completing this program.
DISCLOSURE OF UNLABELED USE
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a clinician relative to diagnostic and treatment options for a specific patient’s medical condition.
DISCLAIMER
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Albert Einstein College of Medicine-Montefiore Medical Center, RealCME or Jazz Pharmaceuticals. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
METHOD OF PARTICIPATION/INSTRUCTIONS ON HOW TO RECEIVE CREDIT
Estimated time to complete this activity: 45 minutes
This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed the post test and evaluation, and have received a digital copy of your credit certificate.
If you are seeking credit, you must complete the post test and evaluation at the conclusion of the activity. Your certificate can be printed immediately.
PRIVACY STATEMENT
Albert Einstein College of Medicine-Montefiore Medical Center, Center for Continuing Professional Development (Einstein-Montefiore) protects the privacy of personal and other information regarding participants and education collaborators. Einstein-Montefiore will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting to the ACCME. Einstein-Montefiore maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information collected from you.
COLLECTION AND USE OF YOUR PERSONAL INFORMATION
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing an activity. Required items include first name, last name, middle initial, degree, email address, address and phone number. These items are necessary. Participants are also required to complete an evaluation of each activity. All evaluative information submitted is collected, retained, and used by Einstein-Montefiore to continuously improve the learning experience. Einstein-Montefiore will not transfer, sell, or share personal information with outside parties or otherwise disclose personal information unless required to in a legal process. Einstein-Montefiore will retain your personal data only for the period necessary to accomplish the stated purposes and to comply with applicable laws.
CONTACT INFORMATION
For questions regarding CME credit, contact Albert Einstein College of Medicine-Montefiore Medical Center at cme@montefiore.org.
For technical questions related to this activity, please contact support@gathered.com.
ACKNOWLEDGEMENT OF FINANCIAL SUPPORT
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Microsoft Edge Google Chrome 60 or higher Mozilla Firefox 60 or higher Apple Safari 11.0 or higher For video, install the latest version of Quicktime. | Supported Phones & Tablets: iOS 9.3 and higher Android 7.0 (Nougat or higher) Microsoft Windows 8 Chrome OS |
| Additional Recommendations and Requirements | |
| Display Resolution & Color Depth | Resolution - 960 X 768 minimum - 1024 X 768 recommended min. Color Depth - 8 bits (256 colors) minimum - 16 bits (High colors) minimum |
| Audio | - Microphone - Speakers or headphones - Audio recording support |
| Word Processing | Software that can open, modify, and save documents in Rich Text Format (RTF). Microsoft Word and PowerPoint are recommended. |
